Angiogenesis and prostate cancer: MicroRNAs comes into view.
暂无分享,去创建一个
Saif Hameed Hlail | A. Jalil | M. Kadhim | J. Gupta | N. Tayyib | Fahad Alsaikhan | P. Ramaiah | U. Vokhidov | Lathamangeswari Chinnasamy | R. Zabibah | Nahla A. Tayyib
[1] Michael R Hamblin,et al. Role of non-coding RNAs in neuroblastoma , 2023, Cancer Gene Therapy.
[2] Michael R Hamblin,et al. Non-coding RNAs and Exosomal Non-coding RNAs in Traumatic Brain Injury: the Small Player with Big Actions , 2023, Molecular Neurobiology.
[3] Wenwei Li,et al. Circ_0005276 Promotes Prostate Cancer Progression Through the Crosstalk of miR-128-3p/DEPDC1B Axis. , 2023, Biochemical genetics.
[4] Yang Xiang,et al. Hsa_circ_0001165 Regulates the Malignant Phenotype and Angiogenesis of Prostate Cancer Cells through miR-654-3p/DDAH1 , 2023, Biotechnology and Bioprocess Engineering.
[5] Ling Zhang,et al. Circ_0057558 accelerates the development of prostate cancer through miR-1238-3p/SEPT2 axis. , 2023, Pathology, research and practice.
[6] Michael R Hamblin,et al. Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression , 2022, Frontiers in Cell and Developmental Biology.
[7] S. Sadeghi,et al. Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis , 2022, Frontiers in Oncology.
[8] A. Jalil,et al. MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells’ Capability to Proliferate and Migrate , 2022, Drug Research.
[9] W. Song,et al. Tumor-derived miR-130b-3p induces cancer-associated fibroblast activation by targeting SPIN90 in luminal A breast cancer , 2022, Oncogenesis.
[10] Arash Salmaninejad,et al. Virus, Exosome, and MicroRNA: New Insights into Autophagy. , 2022, Advances in experimental medicine and biology.
[11] X. Zeng,et al. Research progress on the circRNA/lncRNA-miRNA-mRNA axis in gastric cancer. , 2022, Pathology, research and practice.
[12] Michael R Hamblin,et al. Cytokines and microRNAs in SARS-CoV-2: What do we know? , 2022, Molecular Therapy - Nucleic Acids.
[13] A. Khatami,et al. The expression patterns of MALAT-1, NEAT-1, THRIL, and miR-155-5p in the acute to the post-acute phase of COVID-19 disease , 2022, The Brazilian Journal of Infectious Diseases.
[14] Michael R Hamblin,et al. MicroRNA let-7 and viral infections: focus on mechanisms of action , 2022, Cellular & molecular biology letters.
[15] S. Zappavigna,et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer , 2022, Journal of experimental & clinical cancer research : CR.
[16] P. Mabeta,et al. LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities , 2022, Genes.
[17] Yanan Lu,et al. Circular RNA circ_0062019 exerts oncogenic properties in prostate cancer via mediating miR‐1253/NRBP1 axis , 2021, Andrologia.
[18] L. Jia,et al. miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways , 2021, Experimental and Therapeutic Medicine.
[19] I. Park,et al. miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor , 2021, AntiCancer Research.
[20] Michael R Hamblin,et al. Roles of Non-coding RNAs and Angiogenesis in Glioblastoma , 2021, Frontiers in Cell and Developmental Biology.
[21] Michael R Hamblin,et al. Angiogenesis-related non-coding RNAs and gastrointestinal cancer , 2021, Molecular therapy oncolytics.
[22] Michael R Hamblin,et al. Non-coding RNAs related to angiogenesis in gynecological cancer. , 2021, Gynecologic oncology.
[23] Michael R Hamblin,et al. Cell death pathways and viruses: Role of microRNAs , 2021, Molecular therapy. Nucleic acids.
[24] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[25] Taowei Yang,et al. Circular RNA CircNOLC1, Upregulated by NF-KappaB, Promotes the Progression of Prostate Cancer via miR-647/PAQR4 Axis , 2021, Frontiers in Cell and Developmental Biology.
[26] M. Rubin,et al. Prostate cancer hijacks the microenvironment , 2021, Nature Cell Biology.
[27] Yue-Ming Li,et al. Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers , 2020, Frontiers in Oncology.
[28] M. Moghoofei,et al. The role of HPV gene expression and selected cellular MiRNAs in lung cancer development. , 2020, Microbial pathogenesis.
[29] Xin Wei,et al. Long noncoding RNA LINC00261 suppresses prostate cancer tumorigenesis through upregulation of GATA6-mediated DKK3 , 2020, Cancer cell international.
[30] Arash Salmaninejad,et al. Exosomal microRNAs: novel players in cervical cancer. , 2020, Epigenomics.
[31] Michael R Hamblin,et al. Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. , 2020, Pathology, research and practice.
[32] M. Moghoofei,et al. The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in Prostate cancer. , 2020, International immunopharmacology.
[33] Y. Tao,et al. miRNA-based biomarkers, therapies, and resistance in Cancer , 2020, International journal of biological sciences.
[34] Zhenwei Yang,et al. miR-185 inhibits prostate cancer angiogenesis induced by the nodal/ALK4 pathway , 2020, BMC Urology.
[35] Peng Wang,et al. SP1‐mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR‐377 to facilitate prostate cancer progression through regulation of ZIC5 , 2020, Journal of cellular physiology.
[36] B. Schilling,et al. miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro , 2020, Journal of clinical medicine.
[37] M. Moghoofei,et al. The role of miR‐146a in viral infection , 2019, IUBMB life.
[38] Gonghui Li,et al. lncRNA UCA1 Functions as a ceRNA to Promote Prostate Cancer Progression via Sponging miR143 , 2019, Molecular therapy. Nucleic acids.
[39] A. Vacca,et al. Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs , 2019, Journal of clinical medicine.
[40] Zhenming Jiang,et al. Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1 , 2019, Gene Therapy.
[41] A. Dimberg,et al. Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.
[42] Michael R Hamblin,et al. Pathogenic role of exosomes and microRNAs in HPV‐mediated inflammation and cervical cancer: A review , 2019, International journal of cancer.
[43] Q. Xie,et al. MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis , 2019, Clinical and Translational Oncology.
[44] Zhenming Jiang,et al. Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial–mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2 , 2019, Cancer Cell International.
[45] A. Dudley,et al. Models and molecular mechanisms of blood vessel co-option by cancer cells , 2019, Angiogenesis.
[46] Hamed Mirzaei,et al. microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer , 2019, Journal of cellular physiology.
[47] A. Poprach,et al. MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients , 2019, Cancer Genomics & Proteomics.
[48] F. Boccardo,et al. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer , 2019, Cancers.
[49] Rajesh Singh,et al. Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway , 2019, Cancers.
[50] Junhong Han,et al. miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1 , 2019, BMC cancer.
[51] S. Oltean,et al. Targeting Angiogenesis in Prostate Cancer , 2019, International journal of molecular sciences.
[52] N. Calvo,et al. PTHrP treatment of colon cancer cells promotes tumor associated-angiogenesis by the effect of VEGF , 2019, Molecular and Cellular Endocrinology.
[53] Raghunath Chatterjee,et al. Liquid biopsy: miRNA as a potential biomarker in oral cancer. , 2019, Cancer epidemiology.
[54] Asghar Fallah,et al. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[55] H. Keyvani,et al. microRNAs: Key players in virus‐associated hepatocellular carcinoma , 2018, Journal of cellular physiology.
[56] E. Ruíz-García,et al. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). , 2018, International journal of molecular medicine.
[57] L. Qiang,et al. Codelivery of miR-4638-5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer. , 2018, Molecular pharmaceutics.
[58] O. Bălăcescu,et al. MiRNA-Based Therapeutics in Oncology, Realities, and Challenges , 2018, Antisense Therapy.
[59] P. Barata,et al. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer , 2018, Investigational New Drugs.
[60] Hongwei Zhang,et al. Reciprocal regulations between miRNAs and HIF-1α in human cancers , 2018, Cellular and Molecular Life Sciences.
[61] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[62] Lihang Liu,et al. EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer , 2018, Experimental cell research.
[63] Mohammad Mashreghi,et al. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis , 2018, Journal of cellular physiology.
[64] Hong Chen,et al. miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1 , 2018, Oncology letters.
[65] Jin-Tang Dong,et al. The miR‐203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK‐3β/β‐CATENIN signal pathway , 2018, IUBMB life.
[66] Li Yang,et al. MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901. , 2018, Oncology reports.
[67] N. Dumaz,et al. The role of RICTOR downstream of receptor tyrosine kinase in cancers , 2018, Molecular Cancer.
[68] Cheng Chen,et al. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications , 2018, Molecular Cancer.
[69] G. Zeng,et al. miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression , 2018, Oncology reports.
[70] Zhiqiang Zhang,et al. The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression , 2018, Oncotarget.
[71] B. Jiang,et al. Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer , 2017, Oncotarget.
[72] D. Bailey,et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.
[73] B. Han,et al. MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer , 2017, Cellular Physiology and Biochemistry.
[74] Ning-Bo Hao,et al. The role of miRNA and lncRNA in gastric cancer , 2017, Oncotarget.
[75] F. Winkler. Hostile takeover: how tumours hijack pre‐existing vascular environments to thrive , 2017, The Journal of pathology.
[76] Yi Liu,et al. Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis , 2017, International journal of oncology.
[77] Shaker A. Mousa,et al. The Role of Angiogenesis in Cancer Treatment , 2017, Biomedicines.
[78] H. Zeng,et al. Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-1α. , 2017, Oncotarget.
[79] Antonio Arévalo,et al. Exosomal and Non‐Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis , 2017, The Prostate.
[80] H. Mirzaei,et al. Green tea and its anti-angiogenesis effects. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[81] Chin-Lee Wu,et al. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer , 2017, Molecular Cancer.
[82] P. Pauwels,et al. Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer , 2017, Clinical and Translational Oncology.
[83] Peng Guo,et al. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer , 2016, Oncotarget.
[84] Elena Aréchaga Ocampo,et al. Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer , 2016, Scientific Reports.
[85] A. Hamid,et al. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. , 2016, Acta medica Indonesiana.
[86] Yong-jie Lu,et al. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity , 2016, Oncotarget.
[87] S. Donnini,et al. Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and −186 expression: Novel mechanism of VEGF modulation in prostate cancer , 2016, Oncotarget.
[88] R. Gambari,et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review) , 2016, International journal of oncology.
[89] M. Hendrix,et al. Plasticity underlies tumor progression: role of Nodal signaling , 2016, Cancer and Metastasis Reviews.
[90] Jiang-feng Xu,et al. MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling , 2016, Tumor Biology.
[91] L. A. Antón Aparicio,et al. Role of taxanes in advanced prostate cancer , 2016, Clinical and Translational Oncology.
[92] G. Yousef,et al. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[93] Wen-Juan Ni,et al. Dynamic miRNA–mRNA paradigms: New faces of miRNAs , 2015, Biochemistry and biophysics reports.
[94] Varsha Harish,et al. MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence , 2015, Oncotarget.
[95] Chuanhe Yang,et al. The Role of miR‐21 in Cancer , 2015, Drug development research.
[96] O. Mir,et al. Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis , 2015, Investigational New Drugs.
[97] H. Ying,et al. Hypoxia-inducible miR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in prostate cancer , 2015, Scientific Reports.
[98] B. Zetter,et al. The Contribution of Angiogenesis to the Process of Metastasis. , 2015, Cancer journal.
[99] R. Santi,et al. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity , 2015, Endocrine-related cancer.
[100] Wei-De Zhong,et al. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer , 2015, Clinical Cancer Research.
[101] L. Pereira de Almeida,et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[102] Li Yang,et al. Regulation of circRNA biogenesis , 2015, RNA biology.
[103] J. Moul,et al. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy , 2015, Prostate Cancer and Prostatic Disease.
[104] Jennifer A. Doudna,et al. Dicer-TRBP complex formation ensures accurate mammalian microRNA biogenesis. , 2015, Molecular cell.
[105] Hong Zhu,et al. MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells , 2015, BMC Cancer.
[106] Sung-Hoon Kim,et al. Upregulation of miRNA3195 and miRNA374b Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells , 2015, Journal of Cancer.
[107] V. Baumann,et al. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. , 2014, Future medicinal chemistry.
[108] Jianping Zhang,et al. Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer , 2014, Cancer science.
[109] E. Hirsch,et al. PI3K/AKT signaling pathway and cancer: an updated review , 2014, Annals of medicine.
[110] Qin Chen,et al. MiR‐130b suppresses prostate cancer metastasis through down‐regulation of MMP2 , 2014, Molecular carcinogenesis.
[111] J. Pelling,et al. Apigenin inhibits TGF‐β‐induced VEGF expression in human prostate carcinoma cells via a Smad2/3‐ and Src‐dependent mechanism , 2014, Molecular carcinogenesis.
[112] G. Baldwin,et al. The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer , 2014, Cancer medicine.
[113] F. Saad,et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] Bo Wang,et al. Correction: MiR-130b Is a Prognostic Marker and Inhibits Cell Proliferation and Invasion in Pancreatic Cancer through Targeting STAT3 , 2013, PLoS ONE.
[115] M. Binaschi,et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. , 2013, Neoplasia.
[116] M. Cieśla,et al. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. , 2013, Antioxidants & redox signaling.
[117] Thierry Gil,et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.
[118] Randy S. Schrecengost,et al. Molecular pathogenesis and progression of prostate cancer. , 2013, Seminars in oncology.
[119] M. Carducci,et al. A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). , 2013 .
[120] A. Agarwal,et al. Functional proteomic analysis of seminal plasma proteins in men with various semen parameters , 2013, Reproductive Biology and Endocrinology.
[121] Cheng Huang,et al. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. , 2013, Toxicology.
[122] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[123] A. Llorente,et al. Exosomal miRNAs as Biomarkers for Prostate Cancer , 2013, Front. Genet..
[124] P. Leung,et al. Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells , 2013, PloS one.
[125] Sebastian D. Mackowiak,et al. Circular RNAs are a large class of animal RNAs with regulatory potency , 2013, Nature.
[126] J. Kjems,et al. Natural RNA circles function as efficient microRNA sponges , 2013, Nature.
[127] X. Wan,et al. miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer , 2013, Medical Oncology.
[128] Z. Yao,et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer , 2013, Oncogene.
[129] Yoon-Jae Cho,et al. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. , 2012, Cold Spring Harbor perspectives in medicine.
[130] Lihua Zhang,et al. MiR‐146a suppresses tumor growth and progression by targeting EGFR pathway and in a p‐ERK‐dependent manner in castration‐resistant prostate cancer , 2012, The Prostate.
[131] H. Moses,et al. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk , 2012, Breast Cancer Research.
[132] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[133] Charles Gawad,et al. Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types , 2012, PloS one.
[134] D. Ingber,et al. Forty-Year Journey of Angiogenesis Translational Research , 2011, Science Translational Medicine.
[135] Y. Matsumura,et al. Exosome can prevent RNase from degrading microRNA in feces. , 2011, Journal of gastrointestinal oncology.
[136] U. Huynh-Do,et al. The Role of PTEN in Tumor Angiogenesis , 2011, Journal of oncology.
[137] J. Inazawa,et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. , 2011, Cancer research.
[138] Shafiq A. Khan,et al. Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: Autocrine effects on cell proliferation and migration , 2011, The Prostate.
[139] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[140] B. Jiang,et al. MiR-21 Induced Angiogenesis through AKT and ERK Activation and HIF-1α Expression , 2011, PloS one.
[141] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[142] G. Melillo,et al. Inhibition of Hypoxia Inducible Factor-1α by Dihydroxyphenylethanol, a Product from Olive Oil, Blocks Microsomal Prostaglandin-E Synthase-1/Vascular Endothelial Growth Factor Expression and Reduces Tumor Angiogenesis , 2010, Clinical Cancer Research.
[143] Guanghai Yang,et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). , 2010, Clinica chimica acta; international journal of clinical chemistry.
[144] S. Alahari,et al. miRNA control of tumor cell invasion and metastasis , 2010, International journal of cancer.
[145] Michael K. Wendt,et al. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. , 2009, Future oncology.
[146] Kathryn A. O’Donnell,et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.
[147] V. Kim,et al. Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.
[148] Sarah M Gressett,et al. Intricacies of Bevacizumab-Induced Toxicities and Their Management , 2009, The Annals of pharmacotherapy.
[149] M. Celeste Simon,et al. The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.
[150] Shalini Jain,et al. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. , 2008, Cancer research.
[151] M. Coffey,et al. Hypoxia in prostate cancer: a powerful shield against tumour destruction? , 2008, Cancer treatment reviews.
[152] J. Steitz,et al. Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.
[153] G. Semenza,et al. Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.
[154] K. Ghoshal,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.
[155] D. Bartel,et al. Intronic microRNA precursors that bypass Drosha processing , 2007, Nature.
[156] I. Eltoum,et al. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. , 2007, Cancer research.
[157] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[158] F. Rojo,et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.
[159] D. Sabatini,et al. Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.
[160] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[161] B. Cullen,et al. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. , 2004, RNA.
[162] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[163] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[164] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[165] R. Altman,et al. Investigating hypoxic tumor physiology through gene expression patterns , 2003, Oncogene.
[166] P. Ratcliffe,et al. Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.
[167] M. Goumans,et al. Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.
[168] P. Kantoff,et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[169] M. Kattan,et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[170] P. Kantoff,et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. , 2001, Cancer research.
[171] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[172] J. D. Chapman,et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.
[173] D. Petrylak. Docetaxel (Taxotere) in hormone-refractory prostate cancer. , 2000, Seminars in oncology.
[174] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[175] C. Stein. Mechanisms of action of taxanes in prostate cancer. , 1999, Seminars in oncology.
[176] D. Bostwick,et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. , 1999, Urology.
[177] P. Kantoff,et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.
[178] D. Bostwick,et al. Microvessel density in prostate cancer: prognostic and therapeutic utility. , 1998, Seminars in urologic oncology.
[179] G. Panayotou,et al. Phosphoinositide 3-kinases: a conserved family of signal transducers. , 1997, Trends in biochemical sciences.
[180] V. Laudone,et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.
[181] K. Griffiths,et al. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. , 1996, British Journal of Cancer.
[182] E. Small,et al. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[183] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[184] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[185] J. Folkman,et al. ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.
[186] Michael R Hamblin,et al. Exosomal MicroRNA Profiling. , 2023, Methods in molecular biology.
[187] C. Sáez,et al. Protocols for the Study of Taxanes Chemosensitivity in Prostate Cancer. , 2018, Methods in molecular biology.
[188] S. Sahoo,et al. Exosomes-Based Gene Therapy for MicroRNA Delivery. , 2017, Methods in molecular biology.
[189] Baocun Sun,et al. Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells. , 2017, American journal of cancer research.
[190] B. Xiong,et al. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. , 2013, International journal of oncology.
[191] Wei Wu,et al. MicroRNA-Based Therapeutics for Cancer , 2012, BioDrugs.
[192] D. Reese,et al. Treatment Options in Hormone-Refractory Prostate Cancer , 2012, Drugs.
[193] Robert S Kerbel. Tumor angiogenesis. , 2008, The New England journal of medicine.
[194] G. Semenza,et al. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. , 2004, Cancer detection and prevention.
[195] Lothar Schweigerer,et al. Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy , 2004, Angiogenesis.